Rucaparib monotherapy significantly extended progression-free survival compared with placebo as first-line maintenance treatment for women with ovarian cancer, according to data from a phase 3 clinical trial.

Collaboration among many parties enabled the Phoenix Bioscience Core to become a reality. Guy Reed, MD, MS, dean of the UArizona College of Medicine – Phoenix, is quoted.

“A Look Back: Reflections on Medical History & Artifacts from the Pages of The American Journal of Gastroenterology” is a new book about medical artifacts written by Robert E. Kravetz, MD, FACP, MACG, a College of Medicine – Phoenix associate clinical professor of internal medicine.

The annual event features Mel and Enid Zuckerman College of Public Health student research on sustainable health programs and public health workforce resilience.

Ann-Marie Alameddin led efforts to secure hospital funding, expand telepharmacy in small rural hospitals and develop grant-funded programs.

Rattlesnakes are officially out and about in southern Arizona, and the UArizona Poison and Drug Information Center is reminding you to be aware of your surroundings on your daily hike or walk.

Sandra Kurtin, PhD, ANP-C, AOCN, a hematology/oncology nurse practitioner at the UArizona Cancer Center, outlines the pathophysiology, risks, prognosis, and challenges in patients with myelodysplastic syndromes, as well as therapeutic options and the multidisciplinary management strategies for common adverse events in MDS.

The Phoenix Bioscience Core is home to BacVax, which uses molecular genetics to study Haemophilus influenzae, a common cause of ear infections. It was founded by Terrence Stull, MD, a professor at the University of Arizona College of Medicine – Phoenix, who moved the startup from the College of Medicine – Phoenix to the PBC in July 2021.

University of Arizona graduate programs earned high marks in U.S. News & World Report's Best Graduate Schools rankings. The College of Medicine – Tucson scored high in several categories, including a tie for No. 16 overall on the diversity index and No. 27 in an index measuring how many graduates are practicing direct care in geographic regions that are experiencing health professional shortages.

Treatment with the low-dose painkiller ketamine eased uncontrollable body movements in patients with Parkinson’s disease, according to results from a Phase 2 study sponsored by PharmaTher. Scott Sherman, MD, PhD, director of the Movement Disorders Center and an associate professor of neurology at the College of Medicine – Tucson was the study's principal investigator. This content originated with a Health Sciences news release.